Pfizer Inc. said it is planning on presenting the results of its Community-Acquired Pneumonia Immunization Trial in Adults study next month, and that it may have significant impact on preventing community-acquired pneumonia for seniors.
Results of CAPiTA will be presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases in Hyderabad, India, on March 12. CAPiTA is one of the largest double-blind, randomized, placebo-controlled vaccine efficacy trial ever conducted, and involved 85,000 people over age 65. The primary objective was evaluating the efficacy of Prevenar 13 against community-acquired pneumonia.
“We are pleased with the outcome of the CAPiTA study, which demonstrated that Prevenar 13 can prevent vaccine-type pneumococcal community-acquired pneumonia in adults,” said William Gruber, M.D., senior vice president, Vaccine Clinical Research, Pfizer.
Prevnar 13 was licensed by the FDA under an accelerated approval process to address an “unmet medical need in older adults,” Pfizer said.
